Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group.
In a double blind randomized study, branched-chain amino acids and placebo (casein) were compared as a treatment for chronic hepatic encephalopathy in cirrhosis. After a 15-day run-in period with controlled diet (45-65 g protein), the patients were administered, in addition to their diet, branched-chain amino acids (0.24 g/kg, 30 patients) or an equinitrogenous amount of casein (34 patients). One patient on branched-chain amino acids and two on casein were lost to the study. After 3 months, the index of portal-systemic encephalopathy significantly improved in patients on active treatment (from 40 [S.D. 14]% to 21 [17]), but was not in subjects receiving casein (from 37 [13]% to 36 [12]). Two or more parameters of the index improved in 24 patients treated with amino acids (80%; confidence limits, 61-92%), and only in 12 receiving casein (35%; confidence limits, 20-54%; p less than 0.001). Patients who did not improve were given an alternative treatment for 3 more months. Casein-treated patients given branched-chain amino acids rapidly improved. The changes in neuropsychologic function were associated with an improvement in semiquantitative nitrogen balance, which became consistently positive in amino acid-treated subjects; there was also a mild improvement in nutritional parameters and in liver function tests. The supplementation of oral branched-chain amino acids to the diet is superior to casein as a treatment for providing adequate nitrogen supply and improving the mental state of cirrhotic patients with chronic encephalopathy.
Marchesini
G
G
Istituto di Clinica Medica Generale e Terapia, Università di Bologna, Italy.
Dioguardi
F S
FS
Bianchi
G P
GP
Zoli
M
M
Bellati
G
G
Roffi
L
L
Martines
D
D
Abbiati
R
R
D000328:Adult; D000368:Aged; D000597:Amino Acids, Branched-Chain / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D002364:Caseins / Q000627:therapeutic use; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D005934:Glucagon / Q000097:blood; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood; D008103:Liver Cirrhosis / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009584:Nitrogen / Q000378:metabolism; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D013963:Thyroid Hormones / Q000097:blood
D000597:Amino Acids, Branched-Chain; D001786:Blood Glucose; D002364:Caseins; D007328:Insulin; D010919:Placebos; D013963:Thyroid Hormones; D005934:Glucagon; D009584:Nitrogen